pyrroles has been researched along with Hormone-Dependent Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 1 |
| Barzon, L; Castagliuolo, I; Chiarelotto, G; Dalla Via, L; Ferlin, MG; Gasparotto, V; Palù, G; Pezzi, V | 1 |
| Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G | 1 |
| Groot, K; Halmos, G; Nagy, A; Schally, AV; Szepeshazi, K | 1 |
| Nagy, A; Schally, AV; Szepeshazi, K | 1 |
6 other study(ies) available for pyrroles and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Inhibitory effect of statins on the proliferation of human breast cancer cells.
Topics: Anticholesteremic Agents; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Antagonism; Estradiol; Estrogens; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Neoplasms, Hormone-Dependent; Pyrroles | 2004 |
Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pyrroles; Quinolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2005 |
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Docetaxel; Gene Expression Profiling; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Division; Cell Survival; DNA, Neoplasm; Doxorubicin; Estrogens; Female; Gonadotropin-Releasing Hormone; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Hormone-Dependent; Pyrroles; Receptors, LHRH | 1997 |
Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
Topics: Animals; Antineoplastic Agents; Cell Division; Doxorubicin; Drug Delivery Systems; Estrogens; Female; Gonadotropin-Releasing Hormone; Growth Inhibitors; Injections, Intravenous; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Hormone-Dependent; Pyrroles | 1999 |